Need for additional capital
Development-stage operations require ongoing funding and capital may not be available on acceptable terms.
- Scope
- Operations and pipeline funding
- Materiality
- high
Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing small-molecule medicines for brain conditions with significant unmet need. Its business centers on discovering, developing, and seeking regulatory approval for therapies in epilepsy and other neurological disorders, often through internal programs and licensing or collaboration arrangements.
−581,4 %
−240,1 %
+1 181,3 %
8.97
8.97
| % | |
|---|---|
| Neurology drug candidates | 0% Small-molecule therapies being developed for epilepsy and other brain disorders. |
| Licensing and collaboration revenue | 100% Upfront, milestone, royalty, and other payments from partnered programs. |
| Research and development programs | 0% Internal discovery, preclinical, and clinical development activities for pipeline assets. |
Ovid does not sell commercial drugs today; its economic counterparties are primarily licensing partners, collaborators,...
- Licensing and collaboration partnersprimary
Biopharma counterparties that license rights to Ovid programs or share development economics.
- Future prescriberssecondary
Neurologists and other specialists who would prescribe approved therapies based on efficacy and safety.
- Future patients and caregiverssecondary
Patients with epilepsy and other neurological disorders who would use approved medicines.
- Third-party payorssecondary
Commercial and government payors that influence access, coverage, and reimbursement.
Ovid is headquartered in the United States and operates as a U.S.-based development-stage biopharmaceutical company...
- •Headquartered in the United States
- •Primary operating base is U.S. biopharma development
- •Clinical trials may be conducted in multiple countries
- •Future commercialization would depend on approved market geographies
- •Partnering and regulatory exposure can extend beyond the U.S.
Ovid’s strategy is to advance a focused pipeline of small-molecule medicines for brain conditions with significant...
01
Advance clinical and preclinical neuroscience programsmedium-term
Pipeline progress is the main driver of future value in a development-stage biotech model.
02
Use collaborations and licensing to fund developmentshort-term
Partnership economics can provide non-dilutive capital and external validation.
03
Allocate capital selectively across programsshort-term
A focused funding approach helps concentrate resources on the most promising assets.
Ovid faces the core risks of a development-stage biotech company: clinical failure, regulatory delay, and uncertainty...
Clinical development failure
Drug candidates can fail on efficacy, safety, enrollment, or trial design.
- Scope
- Pipeline programs
- Materiality
- high
Regulatory approval risk
FDA and other regulators may delay, restrict, or deny approval.
- Scope
- All product candidates
- Materiality
- high
Third-party manufacturing dependence
The company does not own manufacturing facilities and relies on external suppliers.
- Scope
- Clinical and future commercial supply
- Materiality
- high
Competitive pressure
Larger pharma and biotech firms may develop better or faster therapies.
- Scope
- Neurology and epilepsy programs
- Materiality
- high
Reimbursement and market access risk
Payor coverage and pricing can limit adoption even if a drug is approved.
- Scope
- Future commercial products
- Materiality
- medium
Revenue recognition for licensing and collaboration agreements
Can create uneven revenue recognition across periods
Accrued clinical and development expenses
Affects R&D expense and liabilities
Stock-based compensation
Impacts operating loss and comparability
Royalty monetization or collaboration-related liabilities
Can add volatility below operating income
4D Molecular Therapeutics, Inc.
FDMT · Biological Products, (No Diagnostic Substances)
UNITED THERAPEUTICS Corp
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
OCULAR THERAPEUTIX, INC
OCUL · Pharmaceutical Preparations
VERU INC.
VERU · Pharmaceutical Preparations
AIM ImmunoTech Inc.
AIM · Biological Products, (No Diagnostic Substances)
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
: 29.4.2026